A Cost-Utility Analysis of LISTEN: Low-Intensity Mental Health Support via Telehealth-Enabled Network for Diabetes Distress.

Value HealthMay 15, 2026 (epub)
Clinical ResearchEndocrinologyPsychiatry

Joahna Kevin Perez, Mary Lou Chatterton, Harish Raj Narandaran et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the cost-effectiveness of the LISTEN program, a low-intensity mental health support via telehealth for adults with diabetes distress. Among 428 participants, the LISTEN group achieved a mean increase in quality-adjusted life-years (QALYs) of 0.024. While costs were lower for LISTEN compared to usual care, these differences were not statistically significant.

Key findings

  • LISTEN resulted in a mean increase of 0.024 QALYs over 6 months.
  • The mean direct cost of delivering LISTEN was A$262 per person.
  • LISTEN had a 94% probability of being cost-effective at a A$50,000 per QALY threshold.
  • Mean health sector costs were lower by A$3271 compared to usual care.

Why it matters

Understanding the cost-effectiveness of mental health interventions in diabetes care is crucial, as it can inform resource allocation and improve patient outcomes. Effective management of diabetes distress can enhance overall health-related quality of life.

What to keep in mind

Findings should be interpreted cautiously due to substantial missing data.

Source

PubMed · PMID 42142561

Published in Value Health. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.